Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Weekly carboplatin and taxotere will be tolerable and effective as second line treatment of
platinum-sensitive ( >6 month treatment free interval) relapsed ovarian cancer
Primary efficacy parameter will be response rate (CR and PR) according to RECIST criteria.
Secondary endpoints will be duration of response, progression free survival and overall
survival. Toxicity will also be evaluated.